Candel Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Candel Therapeutics Stock-Based Compensation Growth & History (CADL)
Candel Therapeutics's stock-based compensation was $3.8M for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.8M | −$1.5M | −28.14% |
| 2024 | 2024-12-31 | $5.3M | $2.2M | +71.85% |
| 2023 | 2023-12-31 | $3.1M | $784,000 | +33.98% |
| 2022 | 2022-12-31 | $2.3M | −$656,000 | −22.14% |
| 2021 | 2021-12-31 | $3.0M | $856,000 | +40.63% |
| 2020 | 2020-12-31 | $2.1M | — | — |
Candel Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.9M | $1.8M | +172.19% |
| Q1 2026 | 2026-03-31 | $1.5M | $1.1M | +362.42% |
| Q4 2025 | 2025-12-31 | $1.3M | $46,000 | +3.70% |
| Q3 2025 | 2025-09-30 | $1.2M | −$21,000 | −1.77% |
| Q2 2025 | 2025-06-30 | $1.1M | −$791,000 | −42.97% |
| Q1 2025 | 2025-03-31 | $314,000 | −$729,000 | −69.89% |
| Q4 2024 | 2024-12-31 | $1.2M | $305,000 | +32.48% |
| Q3 2024 | 2024-09-30 | $1.2M | $498,000 | +72.59% |
| Q2 2024 | 2024-06-30 | $1.8M | $1.1M | +151.16% |
| Q1 2024 | 2024-03-31 | $1.0M | $310,000 | +42.29% |
| Q4 2023 | 2023-12-31 | $939,000 | $305,000 | +48.11% |
| Q3 2023 | 2023-09-30 | $686,000 | −$57,000 | −7.67% |
| Q2 2023 | 2023-06-30 | $733,000 | $295,000 | +67.35% |
| Q1 2023 | 2023-03-31 | $733,000 | $241,000 | +48.98% |
| Q4 2022 | 2022-12-31 | $634,000 | — | — |
| Q3 2022 | 2022-09-30 | $743,000 | −$1.2M | −61.08% |
| Q2 2022 | 2022-06-30 | $438,000 | −$631,000 | −59.03% |
| Q1 2022 | 2022-03-31 | $492,000 | $61,000 | +14.15% |
| Q3 2021 | 2021-09-30 | $1.9M | $1.8M | +2200.00% |
| Q2 2021 | 2021-06-30 | $1.1M | $766,000 | +252.81% |
| Q1 2021 | 2021-03-31 | $431,000 | — | — |
| Q3 2020 | 2020-09-30 | $83,000 | — | — |
| Q2 2020 | 2020-06-30 | $303,000 | — | — |
Candel Therapeutics stock-based compensation trends
Over the last five fiscal years, Candel Therapeutics's stock-based compensation increased from $2.1M to $3.8M, a change of $1.7M. The latest reported quarter, Q2 2026, shows $2.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Candel Therapeutics source filings ↗